Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study
TORONTO and HOUSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ:MDNA TSX:MDNA), a clinical stage immuno-oncology company, today announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist. These data include a confirmed partial response (PR) in a fourth-line metastatic pancreatic ductal adenocarcinoma (PDAC) patient that had previously failed chemo and checkpoint inhibitor therapies. The confirmatory scan for this patient continues to show further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy. Overall, five of fourteen evaluable patients in the ABILITY study’s low and mid-stage dose escalation cohorts have achieved tumor control (PR or stable disease (SD)) with MDNA11 monotherapy.
Related news for (MDNA)
- Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
- Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
- Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
- Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
- Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe